Truist Securities Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $43
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Truist Securities analyst Asthika Goonewardene initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $43.
Truist Securities analyst Asthika Goonewardene initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $43.